3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
29
Lung Neoplasms
16
Small Cell Lung Carcinoma
10
Breast Neoplasms
8
Esophageal Neoplasms
5
Sarcoma
4
Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Advanced Lung Cancer
4
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Widespread Small Cell Lung Cancer
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Uncommon Pathological Types of Lung Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Lung Cancer
1
Interventions
pembrolizumab
38
Nivolumab
24
atezolizumab
10
Ipilimumab
7
Carboplatin
6
avelumab
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Cyclophosphamide
5
fludarabine
4
cabozantinib
4
Specimen Handling
4
Pemetrexed
4
regorafenib
3
Interleukin-2
3
Gemcitabine
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
lenvatinib
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Biopsy
2
Albumin-Bound Paclitaxel
2
zanidatamab
1
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Injections
×
Thoracic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled